CASI CASI Pharmaceuticals: Rasio Kapitalisasi Pasar marang Nilai Buku

CASI Pharmaceuticals minimizes R&D risks by introducing Western oncology drugs into China through licensing agreements. Business growth relies on EVOMELA sales, the development of CID-103, and Asian partnerships, with the metric standing at -0.13. This daily price chart visualizes the stock price action of this drug developer. The brand's high authority in hematology and the trust of medical professionals serve as a solid foundation for the company's further scaling.

CASI Pharmaceuticals, Inc. (CASI) - Rasio Kapitalisasi Pasar marang Nilai Buku saka 04.07.2022 nganti 28.02.2026

CASI (CASI Pharmaceuticals): rincian analitis lan laporan miturut indikator

- rega lan prakiraan konsensus rega:

Rega saham casipharmaceuticals.com|CASI - Target median analis

- data kapitalisasi pasar:

Kapitalisasi pasar CASI|CASI - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- data kapitalisasi buku:

Nilai Buku saben Saham CASI Pharmaceuticals|CASI - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku casipharmaceuticals.com|CASI - Total Aset Bisnis

- data utang lan likuiditas:

Total Utang marang Modal CASI Pharmaceuticals|CASI - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal casipharmaceuticals.com|CASI - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku CASI

Pambiji fundamental:CASI (CASI Pharmaceuticals Inc.)

CASI Pharmaceuticals is developing a cross-border business to introduce Western hematological drugs in China and the US. The value of these assets is compared with the market price of shares to calculate the ratio. This metric determines the investor premium over net tangible assets, separating fundamental value from speculative hype. An increase in the market-to-book ratio signals growing confidence in future earnings. Analyzing this chart helps avoid capital freeze during the revaluation of the issuer.

Pesaing utama